title: Effects of aniracetam on bladder overactivity in rats with cerebral infarction.
abstract: Aniracetam has been used to improve the mental condition of patients with cerebrovascular disease. Previous studies have demonstrated that aniracetam activates the residual functions of cholinergic neurons in damaged brain areas. In this study, the effects of aniracetam on bladder overactivity after left middle cerebral artery occlusion were assessed through oral or i.c.v. administration in sham-operated and cerebral infarcted rats. Oral administration of aniracetam (100 and 300 mg/kg) resulted in a significant and dose-dependent increase in bladder capacity in cerebral infarcted rats but had no effect on bladder capacity in sham-operated rats. Intracerebroventricular administration of aniracetam (0.25 and 2.5 microg/rat) resulted in a significant and dose-dependent increase in bladder capacity in cerebral infarcted rats but not in sham-operated rats. Aniracetam had no significant effect on bladder contraction pressure or micturition threshold pressure in either sham-operated or cerebral infarcted rats. Furthermore, i.c.v. administration of atropine (1 microg/rat), a muscarinic acetylcholine receptor antagonist, completely inhibited the enhancing effects of aniracetam on bladder capacity in cerebral infarcted rats. The effects of aniracetam on bladder overactivity are thought to be mediated in part by activation of cholinergic inhibitory mechanisms in the brain. These results indicate that aniracetam may improve the neurogenic voiding dysfunction observed in patients with cerebrovascular disease.
authors.affiliation: Department of Urology, Kanazawa University School of Medicine, Japan. yasushi_nakada@toyama-chemical.org
authors.forename: Y
authors.initials: Y
authors.lastname: Nakada
authors.forename: O
authors.initials: O
authors.lastname: Yokoyama
authors.forename: K
authors.initials: K
authors.lastname: Komatsu
authors.forename: K
authors.initials: K
authors.lastname: Kodama
authors.forename: S
authors.initials: S
authors.lastname: Yotsuyanagi
authors.forename: S
authors.initials: S
authors.lastname: Niikura
authors.forename: Y
authors.initials: Y
authors.lastname: Nagasaka
authors.forename: M
authors.initials: M
authors.lastname: Namiki
mesh_terms: D000818:Animals; D001285:Atropine / Q000494:pharmacology; D002544:Cerebral Infarction / Q000188:drug therapy / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007276:Injections, Intraventricular; D018696:Neuroprotective Agents / Q000494:pharmacology; D018697:Nootropic Agents / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000502:physiology; D001743:Urinary Bladder / Q000187:drug effects* / Q000502:physiology
chemical_list: D018696:Neuroprotective Agents; D018697:Nootropic Agents; D011760:Pyrrolidinones; D011976:Receptors, Muscarinic; C036466:aniracetam; D001285:Atropine